NASDAQ:GNLX Genelux (GNLX) Stock Price, News & Analysis → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Free GNLX Stock Alerts $3.48 +0.13 (+3.88%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$3.38▼$3.5950-Day Range$3.35▼$8.2552-Week Range$3.33▼$40.98Volume147,729 shsAverage Volume125,291 shsMarket Capitalization$93.49 millionP/E RatioN/ADividend YieldN/APrice Target$34.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Genelux alerts: Email Address Genelux MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside877.0% Upside$34.00 Price TargetShort InterestBearish9.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 5 Articles This WeekInsider TradingSelling Shares$171,851 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.81) to ($1.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.08 out of 5 starsMedical Sector767th out of 909 stocksPharmaceutical Preparations Industry359th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingGenelux has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenelux has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.50% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.Change versus previous monthShort interest in Genelux has recently increased by 1.62%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGenelux does not currently pay a dividend.Dividend GrowthGenelux does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNLX. Previous Next 2.9 News and Social Media Coverage News SentimentGenelux has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Genelux this week, compared to 1 article on an average week.Search Interest2 people have searched for GNLX on MarketBeat in the last 30 days. MarketBeat Follows12 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $171,851.00 in company stock.Percentage Held by Insiders11.70% of the stock of Genelux is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 37.33% of the stock of Genelux is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Genelux are expected to decrease in the coming year, from ($0.81) to ($1.39) per share.Price to Book Value per Share RatioGenelux has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad GoldenCrest MetalsExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More Now About Genelux Stock (NASDAQ:GNLX)Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Read More GNLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNLX Stock News HeadlinesApril 19, 2024 | insidertrades.comGenelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 48,683 SharesApril 20, 2024 | americanbankingnews.comAladar Szalay Sells 48,683 Shares of Genelux Co. (NASDAQ:GNLX) StockApril 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 20, 2024 | investing.comGenelux Corp insider sells shares worth over $250kApril 17, 2024 | msn.comGenelux (GNLX) Price Target Decreased by 22.96% to 26.52April 2, 2024 | investorplace.comGNLX Stock Earnings: Genelux Misses EPS for Q4 2023April 1, 2024 | globenewswire.comGenelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | seekingalpha.comAtossa climbs after cancer therapy updateApril 24, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 15, 2024 | msn.comTD Cowen cuts Immuneering to market perform, cites Phase 1 dataMarch 10, 2024 | msn.comCytomX FY 2023 Earnings PreviewFebruary 23, 2024 | benzinga.comGenelux Stock (NASDAQ:GNLX) Insider TradesFebruary 12, 2024 | msn.comG1 Therapeutics stock dives 36% post-market on P3 study updateFebruary 6, 2024 | msn.comGenelux Corp. Unveils Future-Oriented Corporate PresentationFebruary 3, 2024 | msn.comGenelux Corp. Estimates $23.2 Million in Year-End AssetsJanuary 23, 2024 | finance.yahoo.comHealthcare IT Leaders Adds Health Industry Veteran Mary Mirabelli to Board of DirectorsDecember 21, 2023 | benzinga.comGenelux Stock (NASDAQ:GNLX) Dividends: History, Yield and DatesDecember 15, 2023 | finance.yahoo.comInsider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX)November 27, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Genelux (GNLX) with Buy RecommendationNovember 27, 2023 | msn.comGenelux gets fast track status for Olvi-Vec in ovarian cancerNovember 27, 2023 | msn.comHC Wainwright starts Genelux at buy, cites Olvi-Vec potentialNovember 27, 2023 | markets.businessinsider.comGenelux Says FDA Grants Fast Track Designation For Olvi-Vec To Treat Ovarian CancerNovember 27, 2023 | finance.yahoo.comGenelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian CancerNovember 23, 2023 | benzinga.comGenelux VP Sold $191K In Company StockNovember 17, 2023 | finance.yahoo.comGenelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%November 15, 2023 | msn.comGenelux GAAP EPS of -$0.20 misses by $0.02November 14, 2023 | finance.yahoo.comGenelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesSee More Headlines Receive GNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Next Earnings (Estimated)7/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GNLX CUSIPN/A CIK1231457 Webwww.genelux.com Phone805-267-9889FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$34.00 High Stock Price Target$40.00 Low Stock Price Target$30.00 Potential Upside/Downside+877.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,300,000.00 Net MarginsN/A Pretax Margin-16,645.29% Return on Equity-163.01% Return on Assets-103.37% Debt Debt-to-Equity RatioN/A Current Ratio3.69 Quick Ratio3.69 Sales & Book Value Annual Sales$170,000.00 Price / Sales549.94 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book4.77Miscellaneous Outstanding Shares26,865,000Free Float23,722,000Market Cap$93.49 million OptionableNot Optionable Beta-3.20 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Thomas Zindrick J.D. (Age 65)Chairman, CEO & President Comp: $500kMr. Sean Ryder J.D. (Age 55)General Counsel & Corporate Secretary Comp: $380kMs. Lourie S. Zak (Age 61)CFO & Principal Accounting Officer Dr. Joseph Cappello Ph.D. (Age 67)Chief Technical Officer Comp: $213.08kDr. Yong Yu Ph.D. (Age 53)Senior Vice President of Clinical Development Comp: $242.62kProf. Paul Scigalla M.D. (Age 78)Ph.D., Chief Medical Officer Mr. Ralph Smalling B.Sc. (Age 67)VP & Head of Regulatory Affairs Ms. Caroline Jewett (Age 59)VP & Head of Quality More ExecutivesKey CompetitorsAbeona TherapeuticsNASDAQ:ABEOProPhase LabsNASDAQ:PRPHPMV PharmaceuticalsNASDAQ:PMVPAllakosNASDAQ:ALLKDiaMedica TherapeuticsNASDAQ:DMACView All CompetitorsInsiders & InstitutionsAladar SzalaySold 48,683 sharesTotal: $171,850.99 ($3.53/share)Clarity Capital Partners LLCBought 26,005 shares on 2/20/2024Ownership: 0.097%Woodward Diversified Capital LLCBought 1,037,663 shares on 2/14/2024Ownership: 4.050%Tower Research Capital LLC TRC Bought 2,021 shares on 2/13/2024Ownership: 0.011%Apollon Wealth Management LLCBought 14,006 shares on 2/6/2024Ownership: 0.052%View All Insider TransactionsView All Institutional Transactions GNLX Stock Analysis - Frequently Asked Questions Should I buy or sell Genelux stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GNLX shares. View GNLX analyst ratings or view top-rated stocks. What is Genelux's stock price target for 2024? 4 Wall Street research analysts have issued 1 year price objectives for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's share price to reach $34.00 in the next year. This suggests a possible upside of 877.0% from the stock's current price. View analysts price targets for GNLX or view top-rated stocks among Wall Street analysts. How have GNLX shares performed in 2024? Genelux's stock was trading at $14.01 at the start of the year. Since then, GNLX stock has decreased by 75.2% and is now trading at $3.48. View the best growth stocks for 2024 here. When is Genelux's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 5th 2024. View our GNLX earnings forecast. When did Genelux IPO? Genelux (GNLX) raised $16 million in an IPO on Thursday, January 26th 2023. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO. How do I buy shares of Genelux? Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GNLX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
